Hydroxyl Purine Compounds for Selective PDE2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central and cardiovascular diseases, as well as inflammatory responses, are limited due to the lack of effective PDE2 inhibitors, and existing TNF-α inhibitors have limitations in managing chronic inflammatory diseases.
Innovation Solution
Development of specific hydroxyl purine compounds, as described in Formula (I), and their tautomers or pharmaceutically acceptable salts, which act as PDE2 or TNF-α inhibitors, offering selective inhibition of PDE2 activity and regulation of TNF-α levels to control inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PDE inhibitors (such as caffeine, theophylline, pentoxifylline) are used, then PDE inhibitory activity is achieved, but selectivity for PDE2 is lost
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the purine core structure. The hydroxyl group at position 6 and specific substituents at positions 1, 3, and 7 create localized chemical features that selectively interact with PDE2's active site, achieving PDE2-specific inhibition while maintaining overall PDE inhibitory activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure of purine compounds through different substituent groups (R1, R2, R3, R4, R5, R6, R7) at specific positions. These structural parameter modifications transform non-selective PDE inhibitors into selective PDE2 inhibitors, as evidenced by the specific activity ratios against PDE2 versus other PDE isoforms.
2Object-affected harmful factors
If existing TNF-α inhibitors are used, then inflammatory response control is achieved, but limitations in managing chronic inflammatory diseases remain
Solution Approach 1:
The patent uses PDE2 as an intermediary target to indirectly control TNF-α levels and inflammatory responses. By inhibiting PDE2, the compounds modulate cGMP/cAMP signaling pathways that regulate TNF-α expression, providing an alternative mechanism to direct TNF-α inhibition with potential advantages for chronic disease management.
Data Source
AI summary
Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.